Very interesting Base man! I was unaware that the oncology...

Very interesting Base man!

I was unaware that the oncology assets had been taken off the market?

How did you come to that conclusion may I ask?

If you are right, I think that would not not because Merck wants those assets, but rather that nobody wants to buy them and announcing a "No Sale" would be a very bad look for the CEO and the Board.

So, rather than announce a deal that would disappoint the market, they may have decided to delay any announcements until after the PTSD trial results are released - and the shares are running - and then make that (low sale price) announcement late on a Friday afternoon and hope nobody notices in all the PTSD excitement.

My issue here is that they have been trying to flog these assets for over a year and there appears no progress. Given the hype surrounding each of them, this raises a question of whether teh CEO and management have really "gilded the lilly" all along about these assets..........

In the time that they have been trying to flog these assets they have run down their cash and basically have no net cash. Yes, I know they keep telling us thatthey have cash in the bank - but they conveniently fail to mention the borrowings that essentially offset the cash in the bank.

Money in the bank, w--k, w--k, w--k.

As I have said here before, companies in this space should absolutely NOT be doing research or trials using borrowed money. So expect a cap raise sooner rather than later. And we had all better hope that PTSD trials are wildly positive and not just a borderline outcome............

A capital raising or - as you suggest - a low ball takeover offer in the near term are both quite plausible.

I can almost see the future: another mismanaged Aussie biotech getting taken over on the cheap because the Board and management are too smart by half.

I am or am at risk of being genuinely disappointed.

By the way, I would be disappointed even if the takeover was at $1.50.

But that is just me.............given the high expectations I originally held for Bionomics to become a leading global drug discovery company owned and based in Australia.

Cheers and GLTA.